Neurocrine Biosciences (NBIX) cash on hand

Cash · fiscal 2025
$1.48B

Neurocrine Biosciences (NBIX) held cash of $1.48B at the end of fiscal 2025 (December 31, 2025). That is 37.6% higher than the $1.08B of fiscal 2024. Figures as of 19 Nov 2026, 10:09 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$1.48B
Change on fiscal 2024
+37.6%
Highest on record
$1.48Bfiscal 2025
Lowest on record
$989.30Mfiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Neurocrine Biosciences cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $1.48B in fiscal 2025 and the lowest $989.30M in fiscal 2022.

History · 4 fiscal years

Cash by fiscal year

Neurocrine Biosciences cash on hand, year by year

Neurocrine Biosciences (NBIX) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$1.48B 37.6% up
2024$1.08B 4.3% up
2023$1.03B 4.3% up
2022$989.30M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of Neurocrine Biosciences and comparable companies
CompanyCashFiscal year
Revvity RVTY$919.86M2025
Exelixis EXEL$1.06B2025
Charles River Laboratories International CRL$213.77M2025
Neurocrine Biosciences NBIX$1.48B2025
Ascendis Pharma ASND€616.04M2025
ICON ICLR$647.30M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NBIX

Neurocrine Biosciences, figure by figure

Neurocrine Biosciences (NBIX) overview: price, valuation and scorecardAll health care companies by market value

Neurocrine Biosciences cash on hand: questions and answers

How much cash does Neurocrine Biosciences have?

Neurocrine Biosciences (NBIX) held cash of $1.48B at the end of fiscal 2025 (December 31, 2025). That is 37.6% higher than the $1.08B of fiscal 2024.

What are the highest and lowest cash figures on record for Neurocrine Biosciences?

Across the 4 fiscal years on record (2022–2025), the highest was $1.48B in fiscal 2025 and the lowest $989.30M in fiscal 2022.

How is Neurocrine Biosciences's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone. For Neurocrine Biosciences it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Neurocrine Biosciences (NBIX) cash on hand”, data as of 19 November 2026. https://funkfolio.com/stock/NBIX/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.